Similar articles

• Metabolic effects of hormone deprivation therapy: weighing the evidence.

  Van Londen GJ, Lembersky BC. Van Londen GJ, et al. Oncology (Williston Park). 2010 Aug;24(9):846-7. Oncology (Williston Park). 2010. PMID: 20923042 No abstract available.
• Metabolic syndrome after hormone-modifying therapy: risks associated with antineoplastic therapy.

  Redig AJ, Munshi HG. Redig AJ, et al. Oncology (Williston Park). 2010 Aug;24(9):839-44. Oncology (Williston Park). 2010. PMID: 20923040 Review.
• Postmenopausal women with hormone receptor-positive breast cancer: balancing benefit and toxicity from aromatase inhibitors.

  Ingle JN. Ingle JN. Breast. 2013 Aug;22 Suppl 2:S180-3. doi: 10.1016/j.breast.2013.07.035. Breast. 2013. PMID: 24074784 Review.
• Reply to K.I. Pritchard.

  Fontein DB, van de Velde CJ; International Tamoxifen Exemestane Adjuvant Multinational (TEAM) Global Steering Committee. Fontein DB, et al. J Clin Oncol. 2013 Dec 10;31(35):4477-9. doi: 10.1200/JCO.2013.53.1707. Epub 2013 Nov 4. J Clin Oncol. 2013. PMID: 24190123 No abstract available.
• [Anti-aromatase acting drugs].

  Diedrich K. Diedrich K. Krankenpfl J. 2005;43(4-6):150-1. Krankenpfl J. 2005. PMID: 16171094 German. No abstract available.